TASLY(SH:600535) Sou Hu Cai Jing·2025-08-19 17:34Core Insights - Tianjin Tasly Pharmaceutical Group Co., Ltd. reported a total revenue of 4.288 billion yuan for the first half of 2025, a year-on-year decrease of 1.91% [1] - The company's net profit attributable to shareholders reached 775 million yuan, reflecting a year-on-year increase of 16.97% [1] - The company has a current ratio of 3.314 and a quick ratio of 2.683, indicating strong liquidity [1] Financial Performance - Total revenue for the first half of 2025: 4.288 billion yuan, down 1.91% year-on-year [1] - Net profit attributable to shareholders: 775 million yuan, up 16.97% year-on-year [1] - Non-recurring net profit: 640 million yuan, down 12.87% year-on-year [1] - Asset-liability ratio: 18.43% [1] Market Activity - As of August 19, 2025, the stock price closed at 17.38 yuan, with an increase of 1.94% [1] - Trading volume was 542,100 hands, with a transaction amount of 949.7 million yuan [1] - Main funds experienced a net outflow of 21.79 million yuan, accounting for 2.3% of the transaction amount [1] Company Overview - Tianjin Tasly Pharmaceutical Group was established in 1998 and is primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 14.9395 billion yuan [1] - The company has made investments in 39 enterprises and participated in 5,000 bidding projects [2]